nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—malignant glioma	0.378	1	CbGaD
Bortezomib—CYP1A2—Carmustine—malignant glioma	0.073	0.57	CbGbCtD
Bortezomib—CYP3A4—Temozolomide—malignant glioma	0.0552	0.431	CbGbCtD
Bortezomib—PSMA1—embryo—malignant glioma	0.0042	0.0463	CbGeAlD
Bortezomib—PSMD2—embryo—malignant glioma	0.00312	0.0344	CbGeAlD
Bortezomib—PSMD1—retina—malignant glioma	0.00312	0.0343	CbGeAlD
Bortezomib—PSMD1—telencephalon—malignant glioma	0.00287	0.0316	CbGeAlD
Bortezomib—PSMD2—retina—malignant glioma	0.00276	0.0304	CbGeAlD
Bortezomib—PSMD2—telencephalon—malignant glioma	0.00254	0.028	CbGeAlD
Bortezomib—PSMB1—embryo—malignant glioma	0.0024	0.0264	CbGeAlD
Bortezomib—PSMB2—embryo—malignant glioma	0.00234	0.0258	CbGeAlD
Bortezomib—PSMD1—medulla oblongata—malignant glioma	0.00225	0.0248	CbGeAlD
Bortezomib—PSMB5—telencephalon—malignant glioma	0.00223	0.0246	CbGeAlD
Bortezomib—PSMB2—retina—malignant glioma	0.00207	0.0228	CbGeAlD
Bortezomib—PSMD1—midbrain—malignant glioma	0.00206	0.0227	CbGeAlD
Bortezomib—PSMD1—spinal cord—malignant glioma	0.00201	0.0221	CbGeAlD
Bortezomib—PSMD2—medulla oblongata—malignant glioma	0.002	0.022	CbGeAlD
Bortezomib—PSMB1—telencephalon—malignant glioma	0.00195	0.0215	CbGeAlD
Bortezomib—PSMA1—central nervous system—malignant glioma	0.00194	0.0214	CbGeAlD
Bortezomib—PSMB2—telencephalon—malignant glioma	0.0019	0.0209	CbGeAlD
Bortezomib—PSMA1—cerebellum—malignant glioma	0.0019	0.0209	CbGeAlD
Bortezomib—PSMD2—midbrain—malignant glioma	0.00183	0.0201	CbGeAlD
Bortezomib—PSMD2—spinal cord—malignant glioma	0.00178	0.0196	CbGeAlD
Bortezomib—PSMB5—medulla oblongata—malignant glioma	0.00175	0.0193	CbGeAlD
Bortezomib—PSMB5—midbrain—malignant glioma	0.0016	0.0176	CbGeAlD
Bortezomib—PSMD1—cerebellum—malignant glioma	0.00159	0.0175	CbGeAlD
Bortezomib—PSMB5—spinal cord—malignant glioma	0.00156	0.0172	CbGeAlD
Bortezomib—PSMA1—brain—malignant glioma	0.00154	0.017	CbGeAlD
Bortezomib—Lung infiltration—Carmustine—malignant glioma	0.00154	0.00837	CcSEcCtD
Bortezomib—PSMB1—medulla oblongata—malignant glioma	0.00153	0.0169	CbGeAlD
Bortezomib—Grand mal convulsion—Carmustine—malignant glioma	0.00152	0.00825	CcSEcCtD
Bortezomib—PSMB2—medulla oblongata—malignant glioma	0.0015	0.0165	CbGeAlD
Bortezomib—PSMD2—central nervous system—malignant glioma	0.00144	0.0159	CbGeAlD
Bortezomib—Faecal incontinence—Carmustine—malignant glioma	0.00143	0.00778	CcSEcCtD
Bortezomib—PSMD2—cerebellum—malignant glioma	0.00141	0.0155	CbGeAlD
Bortezomib—PSMB1—midbrain—malignant glioma	0.0014	0.0154	CbGeAlD
Bortezomib—Faecal incontinence—Temozolomide—malignant glioma	0.00138	0.00752	CcSEcCtD
Bortezomib—Transient ischaemic attack—Temozolomide—malignant glioma	0.00138	0.00752	CcSEcCtD
Bortezomib—PSMB2—midbrain—malignant glioma	0.00137	0.015	CbGeAlD
Bortezomib—PSMB1—spinal cord—malignant glioma	0.00137	0.015	CbGeAlD
Bortezomib—Lymphopenia—Temozolomide—malignant glioma	0.00136	0.00742	CcSEcCtD
Bortezomib—Azotaemia—Carmustine—malignant glioma	0.00135	0.00737	CcSEcCtD
Bortezomib—PSMB2—spinal cord—malignant glioma	0.00133	0.0147	CbGeAlD
Bortezomib—Cerebral haemorrhage—Carmustine—malignant glioma	0.0013	0.00709	CcSEcCtD
Bortezomib—SLC31A1—medulla oblongata—malignant glioma	0.00129	0.0143	CbGeAlD
Bortezomib—PSMD1—brain—malignant glioma	0.00129	0.0143	CbGeAlD
Bortezomib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00126	0.00685	CcSEcCtD
Bortezomib—PSMB5—cerebellum—malignant glioma	0.00124	0.0136	CbGeAlD
Bortezomib—Febrile neutropenia—Carmustine—malignant glioma	0.0012	0.00653	CcSEcCtD
Bortezomib—SLC31A1—midbrain—malignant glioma	0.00118	0.013	CbGeAlD
Bortezomib—Febrile neutropenia—Temozolomide—malignant glioma	0.00116	0.00631	CcSEcCtD
Bortezomib—SLC31A1—spinal cord—malignant glioma	0.00115	0.0127	CbGeAlD
Bortezomib—PSMD2—brain—malignant glioma	0.00115	0.0126	CbGeAlD
Bortezomib—Deep vein thrombosis—Temozolomide—malignant glioma	0.00115	0.00624	CcSEcCtD
Bortezomib—PSMB8—brain—malignant glioma	0.00114	0.0125	CbGeAlD
Bortezomib—Oral candidiasis—Carmustine—malignant glioma	0.00114	0.00618	CcSEcCtD
Bortezomib—Encephalopathy—Carmustine—malignant glioma	0.00112	0.00612	CcSEcCtD
Bortezomib—PSMB1—central nervous system—malignant glioma	0.00111	0.0122	CbGeAlD
Bortezomib—PTGS1—endothelium—malignant glioma	0.0011	0.0121	CbGeAlD
Bortezomib—Oral candidiasis—Temozolomide—malignant glioma	0.0011	0.00597	CcSEcCtD
Bortezomib—PSMB1—cerebellum—malignant glioma	0.00108	0.0119	CbGeAlD
Bortezomib—PSMB2—central nervous system—malignant glioma	0.00108	0.0119	CbGeAlD
Bortezomib—Cyst—Carmustine—malignant glioma	0.00108	0.00587	CcSEcCtD
Bortezomib—Parosmia—Temozolomide—malignant glioma	0.00108	0.00585	CcSEcCtD
Bortezomib—PSMB2—cerebellum—malignant glioma	0.00106	0.0116	CbGeAlD
Bortezomib—Interstitial lung disease—Carmustine—malignant glioma	0.00102	0.00555	CcSEcCtD
Bortezomib—PTGS1—blood vessel—malignant glioma	0.00101	0.0112	CbGeAlD
Bortezomib—PSMB5—brain—malignant glioma	0.00101	0.0111	CbGeAlD
Bortezomib—Myopathy—Temozolomide—malignant glioma	0.000995	0.00541	CcSEcCtD
Bortezomib—Lung disorder—Temozolomide—malignant glioma	0.000985	0.00536	CcSEcCtD
Bortezomib—Interstitial lung disease—Temozolomide—malignant glioma	0.000985	0.00536	CcSEcCtD
Bortezomib—Scotoma—Carmustine—malignant glioma	0.00095	0.00517	CcSEcCtD
Bortezomib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.000942	0.00513	CcSEcCtD
Bortezomib—SLC31A1—central nervous system—malignant glioma	0.000937	0.0103	CbGeAlD
Bortezomib—Hepatotoxicity—Carmustine—malignant glioma	0.000935	0.00509	CcSEcCtD
Bortezomib—Herpes zoster—Temozolomide—malignant glioma	0.000926	0.00504	CcSEcCtD
Bortezomib—Cholestasis—Temozolomide—malignant glioma	0.000918	0.005	CcSEcCtD
Bortezomib—Scotoma—Temozolomide—malignant glioma	0.000918	0.005	CcSEcCtD
Bortezomib—SLC31A1—cerebellum—malignant glioma	0.000915	0.0101	CbGeAlD
Bortezomib—Hepatotoxicity—Temozolomide—malignant glioma	0.000903	0.00491	CcSEcCtD
Bortezomib—Coagulopathy—Temozolomide—malignant glioma	0.000896	0.00487	CcSEcCtD
Bortezomib—Injection site pain—Carmustine—malignant glioma	0.000884	0.00481	CcSEcCtD
Bortezomib—PSMB1—brain—malignant glioma	0.00088	0.00969	CbGeAlD
Bortezomib—PSMB2—brain—malignant glioma	0.000859	0.00945	CbGeAlD
Bortezomib—Rigors—Temozolomide—malignant glioma	0.000854	0.00465	CcSEcCtD
Bortezomib—Petechiae—Temozolomide—malignant glioma	0.000848	0.00461	CcSEcCtD
Bortezomib—Endocrine disorder—Temozolomide—malignant glioma	0.000841	0.00458	CcSEcCtD
Bortezomib—Speech disorder—Carmustine—malignant glioma	0.000839	0.00457	CcSEcCtD
Bortezomib—Extravasation—Carmustine—malignant glioma	0.000827	0.0045	CcSEcCtD
Bortezomib—Speech disorder—Temozolomide—malignant glioma	0.000811	0.00441	CcSEcCtD
Bortezomib—Disturbance in attention—Temozolomide—malignant glioma	0.000805	0.00438	CcSEcCtD
Bortezomib—Viral infection—Temozolomide—malignant glioma	0.000772	0.0042	CcSEcCtD
Bortezomib—Leukocytosis—Carmustine—malignant glioma	0.000768	0.00418	CcSEcCtD
Bortezomib—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000767	0.00417	CcSEcCtD
Bortezomib—Herpes simplex—Temozolomide—malignant glioma	0.000757	0.00412	CcSEcCtD
Bortezomib—SLC31A1—brain—malignant glioma	0.000744	0.00819	CbGeAlD
Bortezomib—Gait disturbance—Carmustine—malignant glioma	0.000739	0.00402	CcSEcCtD
Bortezomib—Hearing impaired—Temozolomide—malignant glioma	0.000733	0.00399	CcSEcCtD
Bortezomib—Pulmonary embolism—Carmustine—malignant glioma	0.000722	0.00393	CcSEcCtD
Bortezomib—Injection site reaction—Carmustine—malignant glioma	0.000717	0.0039	CcSEcCtD
Bortezomib—Gait disturbance—Temozolomide—malignant glioma	0.000715	0.00389	CcSEcCtD
Bortezomib—Respiratory failure—Temozolomide—malignant glioma	0.00071	0.00386	CcSEcCtD
Bortezomib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000706	0.00384	CcSEcCtD
Bortezomib—Pulmonary embolism—Temozolomide—malignant glioma	0.000697	0.00379	CcSEcCtD
Bortezomib—Urinary incontinence—Carmustine—malignant glioma	0.000697	0.00379	CcSEcCtD
Bortezomib—Candida infection—Carmustine—malignant glioma	0.000689	0.00375	CcSEcCtD
Bortezomib—Neuropathy—Carmustine—malignant glioma	0.000678	0.00369	CcSEcCtD
Bortezomib—Urinary incontinence—Temozolomide—malignant glioma	0.000673	0.00366	CcSEcCtD
Bortezomib—Candida infection—Temozolomide—malignant glioma	0.000666	0.00362	CcSEcCtD
Bortezomib—Nateglinide—PPARG—malignant glioma	0.000661	0.575	CrCbGaD
Bortezomib—Coma—Carmustine—malignant glioma	0.000659	0.00359	CcSEcCtD
Bortezomib—Neuropathy—Temozolomide—malignant glioma	0.000655	0.00356	CcSEcCtD
Bortezomib—Neoplasm—Carmustine—malignant glioma	0.000653	0.00355	CcSEcCtD
Bortezomib—Dry eye—Temozolomide—malignant glioma	0.000644	0.0035	CcSEcCtD
Bortezomib—Neoplasm—Temozolomide—malignant glioma	0.000631	0.00343	CcSEcCtD
Bortezomib—Abnormal vision—Carmustine—malignant glioma	0.000629	0.00342	CcSEcCtD
Bortezomib—Sepsis—Carmustine—malignant glioma	0.000626	0.00341	CcSEcCtD
Bortezomib—Abnormal vision—Temozolomide—malignant glioma	0.000608	0.00331	CcSEcCtD
Bortezomib—Phlebitis—Carmustine—malignant glioma	0.000608	0.00331	CcSEcCtD
Bortezomib—Thrombophlebitis—Carmustine—malignant glioma	0.000605	0.00329	CcSEcCtD
Bortezomib—Diabetes mellitus—Carmustine—malignant glioma	0.000602	0.00328	CcSEcCtD
Bortezomib—Thrombophlebitis—Temozolomide—malignant glioma	0.000585	0.00318	CcSEcCtD
Bortezomib—Eye pain—Carmustine—malignant glioma	0.00058	0.00316	CcSEcCtD
Bortezomib—Gastroenteritis—Temozolomide—malignant glioma	0.000571	0.00311	CcSEcCtD
Bortezomib—Vascular purpura—Temozolomide—malignant glioma	0.000566	0.00308	CcSEcCtD
Bortezomib—Deafness—Temozolomide—malignant glioma	0.000566	0.00308	CcSEcCtD
Bortezomib—Hepatic failure—Temozolomide—malignant glioma	0.000563	0.00307	CcSEcCtD
Bortezomib—Eye pain—Temozolomide—malignant glioma	0.000561	0.00305	CcSEcCtD
Bortezomib—Amnesia—Carmustine—malignant glioma	0.000558	0.00303	CcSEcCtD
Bortezomib—Amnesia—Temozolomide—malignant glioma	0.000539	0.00293	CcSEcCtD
Bortezomib—Thirst—Temozolomide—malignant glioma	0.000532	0.00289	CcSEcCtD
Bortezomib—Hyponatraemia—Carmustine—malignant glioma	0.000526	0.00286	CcSEcCtD
Bortezomib—Purpura—Temozolomide—malignant glioma	0.000525	0.00286	CcSEcCtD
Bortezomib—Diplopia—Carmustine—malignant glioma	0.000524	0.00285	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000524	0.00285	CcSEcCtD
Bortezomib—Diplopia—Temozolomide—malignant glioma	0.000506	0.00275	CcSEcCtD
Bortezomib—Face oedema—Carmustine—malignant glioma	0.000506	0.00275	CcSEcCtD
Bortezomib—Ataxia—Carmustine—malignant glioma	0.000493	0.00268	CcSEcCtD
Bortezomib—PTGS1—telencephalon—malignant glioma	0.000492	0.00541	CbGeAlD
Bortezomib—Face oedema—Temozolomide—malignant glioma	0.000489	0.00266	CcSEcCtD
Bortezomib—Nateglinide—PTGS1—malignant glioma	0.000488	0.425	CrCbGaD
Bortezomib—Hypokalaemia—Carmustine—malignant glioma	0.000477	0.00259	CcSEcCtD
Bortezomib—Ataxia—Temozolomide—malignant glioma	0.000476	0.00259	CcSEcCtD
Bortezomib—Dehydration—Temozolomide—malignant glioma	0.000471	0.00256	CcSEcCtD
Bortezomib—Dry skin—Temozolomide—malignant glioma	0.000464	0.00252	CcSEcCtD
Bortezomib—Muscular weakness—Carmustine—malignant glioma	0.000462	0.00251	CcSEcCtD
Bortezomib—Hypokalaemia—Temozolomide—malignant glioma	0.000461	0.00251	CcSEcCtD
Bortezomib—Breast disorder—Temozolomide—malignant glioma	0.000458	0.00249	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000456	0.00248	CcSEcCtD
Bortezomib—CYP2D6—brainstem—malignant glioma	0.000455	0.00501	CbGeAlD
Bortezomib—Dysphagia—Carmustine—malignant glioma	0.000453	0.00246	CcSEcCtD
Bortezomib—Muscular weakness—Temozolomide—malignant glioma	0.000447	0.00243	CcSEcCtD
Bortezomib—Abdominal distension—Temozolomide—malignant glioma	0.000441	0.0024	CcSEcCtD
Bortezomib—Dysphagia—Temozolomide—malignant glioma	0.000438	0.00238	CcSEcCtD
Bortezomib—Pancytopenia—Carmustine—malignant glioma	0.00043	0.00234	CcSEcCtD
Bortezomib—Neutropenia—Carmustine—malignant glioma	0.000423	0.0023	CcSEcCtD
Bortezomib—Bronchitis—Temozolomide—malignant glioma	0.000421	0.00229	CcSEcCtD
Bortezomib—Pancytopenia—Temozolomide—malignant glioma	0.000416	0.00226	CcSEcCtD
Bortezomib—Neutropenia—Temozolomide—malignant glioma	0.000409	0.00223	CcSEcCtD
Bortezomib—Hyperglycaemia—Carmustine—malignant glioma	0.000408	0.00222	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000407	0.00221	CcSEcCtD
Bortezomib—Pneumonia—Carmustine—malignant glioma	0.000406	0.00221	CcSEcCtD
Bortezomib—Pollakiuria—Temozolomide—malignant glioma	0.000404	0.0022	CcSEcCtD
Bortezomib—CYP2D6—telencephalon—malignant glioma	0.000404	0.00445	CbGeAlD
Bortezomib—Erectile dysfunction—Temozolomide—malignant glioma	0.000403	0.00219	CcSEcCtD
Bortezomib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000399	0.00217	CcSEcCtD
Bortezomib—Weight increased—Temozolomide—malignant glioma	0.000398	0.00217	CcSEcCtD
Bortezomib—Renal failure—Carmustine—malignant glioma	0.000397	0.00216	CcSEcCtD
Bortezomib—Weight decreased—Temozolomide—malignant glioma	0.000396	0.00215	CcSEcCtD
Bortezomib—Neuropathy peripheral—Carmustine—malignant glioma	0.000396	0.00215	CcSEcCtD
Bortezomib—Hyperglycaemia—Temozolomide—malignant glioma	0.000395	0.00215	CcSEcCtD
Bortezomib—Stomatitis—Carmustine—malignant glioma	0.000394	0.00214	CcSEcCtD
Bortezomib—Urinary tract infection—Carmustine—malignant glioma	0.000392	0.00214	CcSEcCtD
Bortezomib—Pneumonia—Temozolomide—malignant glioma	0.000392	0.00214	CcSEcCtD
Bortezomib—Infestation—Temozolomide—malignant glioma	0.00039	0.00212	CcSEcCtD
Bortezomib—Infestation NOS—Temozolomide—malignant glioma	0.00039	0.00212	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000387	0.0021	CcSEcCtD
Bortezomib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000382	0.00208	CcSEcCtD
Bortezomib—Stomatitis—Temozolomide—malignant glioma	0.00038	0.00207	CcSEcCtD
Bortezomib—Urinary tract infection—Temozolomide—malignant glioma	0.000379	0.00206	CcSEcCtD
Bortezomib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000369	0.00201	CcSEcCtD
Bortezomib—Sinusitis—Temozolomide—malignant glioma	0.000366	0.00199	CcSEcCtD
Bortezomib—Haemoglobin—Carmustine—malignant glioma	0.000364	0.00198	CcSEcCtD
Bortezomib—Haemorrhage—Carmustine—malignant glioma	0.000362	0.00197	CcSEcCtD
Bortezomib—Hallucination—Carmustine—malignant glioma	0.000361	0.00196	CcSEcCtD
Bortezomib—Hypoaesthesia—Carmustine—malignant glioma	0.000361	0.00196	CcSEcCtD
Bortezomib—Oedema peripheral—Carmustine—malignant glioma	0.000357	0.00194	CcSEcCtD
Bortezomib—Connective tissue disorder—Carmustine—malignant glioma	0.000356	0.00194	CcSEcCtD
Bortezomib—Haemoglobin—Temozolomide—malignant glioma	0.000352	0.00192	CcSEcCtD
Bortezomib—Hepatitis—Temozolomide—malignant glioma	0.00035	0.00191	CcSEcCtD
Bortezomib—Haemorrhage—Temozolomide—malignant glioma	0.00035	0.00191	CcSEcCtD
Bortezomib—Visual impairment—Carmustine—malignant glioma	0.000349	0.0019	CcSEcCtD
Bortezomib—Hallucination—Temozolomide—malignant glioma	0.000348	0.0019	CcSEcCtD
Bortezomib—Hypoaesthesia—Temozolomide—malignant glioma	0.000348	0.0019	CcSEcCtD
Bortezomib—Urinary tract disorder—Temozolomide—malignant glioma	0.000346	0.00188	CcSEcCtD
Bortezomib—Oedema peripheral—Temozolomide—malignant glioma	0.000345	0.00188	CcSEcCtD
Bortezomib—PTGS1—spinal cord—malignant glioma	0.000344	0.00379	CbGeAlD
Bortezomib—Connective tissue disorder—Temozolomide—malignant glioma	0.000344	0.00187	CcSEcCtD
Bortezomib—Urethral disorder—Temozolomide—malignant glioma	0.000343	0.00187	CcSEcCtD
Bortezomib—Eye disorder—Carmustine—malignant glioma	0.000339	0.00184	CcSEcCtD
Bortezomib—Visual impairment—Temozolomide—malignant glioma	0.000338	0.00184	CcSEcCtD
Bortezomib—Flushing—Carmustine—malignant glioma	0.000336	0.00183	CcSEcCtD
Bortezomib—Erythema multiforme—Temozolomide—malignant glioma	0.000331	0.0018	CcSEcCtD
Bortezomib—Eye disorder—Temozolomide—malignant glioma	0.000327	0.00178	CcSEcCtD
Bortezomib—Tinnitus—Temozolomide—malignant glioma	0.000327	0.00178	CcSEcCtD
Bortezomib—Flushing—Temozolomide—malignant glioma	0.000325	0.00177	CcSEcCtD
Bortezomib—Cardiac disorder—Temozolomide—malignant glioma	0.000325	0.00177	CcSEcCtD
Bortezomib—Arrhythmia—Carmustine—malignant glioma	0.000324	0.00176	CcSEcCtD
Bortezomib—CYP1A1—central nervous system—malignant glioma	0.000318	0.0035	CbGeAlD
Bortezomib—Angiopathy—Temozolomide—malignant glioma	0.000318	0.00173	CcSEcCtD
Bortezomib—Mental disorder—Carmustine—malignant glioma	0.000318	0.00173	CcSEcCtD
Bortezomib—Immune system disorder—Temozolomide—malignant glioma	0.000316	0.00172	CcSEcCtD
Bortezomib—Mediastinal disorder—Temozolomide—malignant glioma	0.000316	0.00172	CcSEcCtD
Bortezomib—Erythema—Carmustine—malignant glioma	0.000315	0.00172	CcSEcCtD
Bortezomib—Malnutrition—Carmustine—malignant glioma	0.000315	0.00172	CcSEcCtD
Bortezomib—Chills—Temozolomide—malignant glioma	0.000314	0.00171	CcSEcCtD
Bortezomib—Mental disorder—Temozolomide—malignant glioma	0.000307	0.00167	CcSEcCtD
Bortezomib—Back pain—Carmustine—malignant glioma	0.000305	0.00166	CcSEcCtD
Bortezomib—Erythema—Temozolomide—malignant glioma	0.000305	0.00166	CcSEcCtD
Bortezomib—Malnutrition—Temozolomide—malignant glioma	0.000305	0.00166	CcSEcCtD
Bortezomib—Dysgeusia—Temozolomide—malignant glioma	0.000299	0.00162	CcSEcCtD
Bortezomib—Vision blurred—Carmustine—malignant glioma	0.000297	0.00162	CcSEcCtD
Bortezomib—Tremor—Carmustine—malignant glioma	0.000296	0.00161	CcSEcCtD
Bortezomib—Back pain—Temozolomide—malignant glioma	0.000295	0.0016	CcSEcCtD
Bortezomib—Anaemia—Carmustine—malignant glioma	0.000292	0.00159	CcSEcCtD
Bortezomib—Agitation—Carmustine—malignant glioma	0.00029	0.00158	CcSEcCtD
Bortezomib—Vision blurred—Temozolomide—malignant glioma	0.000287	0.00156	CcSEcCtD
Bortezomib—Tremor—Temozolomide—malignant glioma	0.000286	0.00155	CcSEcCtD
Bortezomib—Ill-defined disorder—Temozolomide—malignant glioma	0.000283	0.00154	CcSEcCtD
Bortezomib—Leukopenia—Carmustine—malignant glioma	0.000282	0.00154	CcSEcCtD
Bortezomib—Anaemia—Temozolomide—malignant glioma	0.000282	0.00153	CcSEcCtD
Bortezomib—Agitation—Temozolomide—malignant glioma	0.00028	0.00152	CcSEcCtD
Bortezomib—PTGS1—central nervous system—malignant glioma	0.000279	0.00308	CbGeAlD
Bortezomib—Angioedema—Temozolomide—malignant glioma	0.000279	0.00152	CcSEcCtD
Bortezomib—Malaise—Temozolomide—malignant glioma	0.000275	0.0015	CcSEcCtD
Bortezomib—Vertigo—Temozolomide—malignant glioma	0.000274	0.00149	CcSEcCtD
Bortezomib—CYP2C8—brain—malignant glioma	0.000274	0.00301	CbGeAlD
Bortezomib—Convulsion—Carmustine—malignant glioma	0.000273	0.00149	CcSEcCtD
Bortezomib—Leukopenia—Temozolomide—malignant glioma	0.000273	0.00148	CcSEcCtD
Bortezomib—Hypertension—Carmustine—malignant glioma	0.000272	0.00148	CcSEcCtD
Bortezomib—Palpitations—Temozolomide—malignant glioma	0.000269	0.00147	CcSEcCtD
Bortezomib—Chest pain—Carmustine—malignant glioma	0.000269	0.00146	CcSEcCtD
Bortezomib—Myalgia—Carmustine—malignant glioma	0.000269	0.00146	CcSEcCtD
Bortezomib—Anxiety—Carmustine—malignant glioma	0.000268	0.00146	CcSEcCtD
Bortezomib—Cough—Temozolomide—malignant glioma	0.000266	0.00145	CcSEcCtD
Bortezomib—Convulsion—Temozolomide—malignant glioma	0.000264	0.00144	CcSEcCtD
Bortezomib—Hypertension—Temozolomide—malignant glioma	0.000263	0.00143	CcSEcCtD
Bortezomib—Confusional state—Carmustine—malignant glioma	0.00026	0.00141	CcSEcCtD
Bortezomib—Arthralgia—Temozolomide—malignant glioma	0.00026	0.00141	CcSEcCtD
Bortezomib—Myalgia—Temozolomide—malignant glioma	0.00026	0.00141	CcSEcCtD
Bortezomib—Anxiety—Temozolomide—malignant glioma	0.000259	0.00141	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000258	0.0014	CcSEcCtD
Bortezomib—Oedema—Carmustine—malignant glioma	0.000257	0.0014	CcSEcCtD
Bortezomib—Discomfort—Temozolomide—malignant glioma	0.000256	0.0014	CcSEcCtD
Bortezomib—Infection—Carmustine—malignant glioma	0.000256	0.00139	CcSEcCtD
Bortezomib—CYP1A1—brain—malignant glioma	0.000253	0.00278	CbGeAlD
Bortezomib—Thrombocytopenia—Carmustine—malignant glioma	0.000252	0.00137	CcSEcCtD
Bortezomib—Tachycardia—Carmustine—malignant glioma	0.000251	0.00137	CcSEcCtD
Bortezomib—Confusional state—Temozolomide—malignant glioma	0.000251	0.00137	CcSEcCtD
Bortezomib—Oedema—Temozolomide—malignant glioma	0.000249	0.00135	CcSEcCtD
Bortezomib—Anaphylactic shock—Temozolomide—malignant glioma	0.000249	0.00135	CcSEcCtD
Bortezomib—Infection—Temozolomide—malignant glioma	0.000247	0.00134	CcSEcCtD
Bortezomib—Anorexia—Carmustine—malignant glioma	0.000245	0.00134	CcSEcCtD
Bortezomib—Nervous system disorder—Temozolomide—malignant glioma	0.000244	0.00133	CcSEcCtD
Bortezomib—Thrombocytopenia—Temozolomide—malignant glioma	0.000244	0.00133	CcSEcCtD
Bortezomib—Skin disorder—Temozolomide—malignant glioma	0.000242	0.00131	CcSEcCtD
Bortezomib—Hypotension—Carmustine—malignant glioma	0.000241	0.00131	CcSEcCtD
Bortezomib—Hyperhidrosis—Temozolomide—malignant glioma	0.000241	0.00131	CcSEcCtD
Bortezomib—Anorexia—Temozolomide—malignant glioma	0.000237	0.00129	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000235	0.00128	CcSEcCtD
Bortezomib—CYP3A4—central nervous system—malignant glioma	0.000233	0.00257	CbGeAlD
Bortezomib—Insomnia—Carmustine—malignant glioma	0.000233	0.00127	CcSEcCtD
Bortezomib—Paraesthesia—Carmustine—malignant glioma	0.000231	0.00126	CcSEcCtD
Bortezomib—CYP2D6—central nervous system—malignant glioma	0.00023	0.00253	CbGeAlD
Bortezomib—Dyspnoea—Carmustine—malignant glioma	0.00023	0.00125	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000227	0.00123	CcSEcCtD
Bortezomib—Insomnia—Temozolomide—malignant glioma	0.000225	0.00122	CcSEcCtD
Bortezomib—CYP2D6—cerebellum—malignant glioma	0.000225	0.00247	CbGeAlD
Bortezomib—Decreased appetite—Carmustine—malignant glioma	0.000224	0.00122	CcSEcCtD
Bortezomib—Paraesthesia—Temozolomide—malignant glioma	0.000223	0.00122	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000222	0.00121	CcSEcCtD
Bortezomib—PTGS1—brain—malignant glioma	0.000222	0.00244	CbGeAlD
Bortezomib—Dyspnoea—Temozolomide—malignant glioma	0.000222	0.00121	CcSEcCtD
Bortezomib—Pain—Carmustine—malignant glioma	0.00022	0.0012	CcSEcCtD
Bortezomib—Constipation—Carmustine—malignant glioma	0.00022	0.0012	CcSEcCtD
Bortezomib—Dyspepsia—Temozolomide—malignant glioma	0.000219	0.00119	CcSEcCtD
Bortezomib—Decreased appetite—Temozolomide—malignant glioma	0.000216	0.00118	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000215	0.00117	CcSEcCtD
Bortezomib—Fatigue—Temozolomide—malignant glioma	0.000215	0.00117	CcSEcCtD
Bortezomib—Pain—Temozolomide—malignant glioma	0.000213	0.00116	CcSEcCtD
Bortezomib—Constipation—Temozolomide—malignant glioma	0.000213	0.00116	CcSEcCtD
Bortezomib—Feeling abnormal—Carmustine—malignant glioma	0.000212	0.00115	CcSEcCtD
Bortezomib—Gastrointestinal pain—Carmustine—malignant glioma	0.000211	0.00115	CcSEcCtD
Bortezomib—Feeling abnormal—Temozolomide—malignant glioma	0.000205	0.00112	CcSEcCtD
Bortezomib—Abdominal pain—Carmustine—malignant glioma	0.000204	0.00111	CcSEcCtD
Bortezomib—Body temperature increased—Carmustine—malignant glioma	0.000204	0.00111	CcSEcCtD
Bortezomib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000203	0.00111	CcSEcCtD
Bortezomib—Urticaria—Temozolomide—malignant glioma	0.000198	0.00108	CcSEcCtD
Bortezomib—Body temperature increased—Temozolomide—malignant glioma	0.000197	0.00107	CcSEcCtD
Bortezomib—Abdominal pain—Temozolomide—malignant glioma	0.000197	0.00107	CcSEcCtD
Bortezomib—Hypersensitivity—Carmustine—malignant glioma	0.00019	0.00103	CcSEcCtD
Bortezomib—Asthenia—Carmustine—malignant glioma	0.000185	0.00101	CcSEcCtD
Bortezomib—Hypersensitivity—Temozolomide—malignant glioma	0.000183	0.000997	CcSEcCtD
Bortezomib—CYP2D6—brain—malignant glioma	0.000182	0.00201	CbGeAlD
Bortezomib—Asthenia—Temozolomide—malignant glioma	0.000179	0.000971	CcSEcCtD
Bortezomib—Diarrhoea—Carmustine—malignant glioma	0.000176	0.000959	CcSEcCtD
Bortezomib—Pruritus—Temozolomide—malignant glioma	0.000176	0.000958	CcSEcCtD
Bortezomib—Dizziness—Carmustine—malignant glioma	0.00017	0.000926	CcSEcCtD
Bortezomib—Diarrhoea—Temozolomide—malignant glioma	0.00017	0.000926	CcSEcCtD
Bortezomib—Dizziness—Temozolomide—malignant glioma	0.000165	0.000895	CcSEcCtD
Bortezomib—Vomiting—Carmustine—malignant glioma	0.000164	0.000891	CcSEcCtD
Bortezomib—Rash—Carmustine—malignant glioma	0.000162	0.000883	CcSEcCtD
Bortezomib—Dermatitis—Carmustine—malignant glioma	0.000162	0.000882	CcSEcCtD
Bortezomib—Headache—Carmustine—malignant glioma	0.000161	0.000878	CcSEcCtD
Bortezomib—Vomiting—Temozolomide—malignant glioma	0.000158	0.000861	CcSEcCtD
Bortezomib—Rash—Temozolomide—malignant glioma	0.000157	0.000854	CcSEcCtD
Bortezomib—Dermatitis—Temozolomide—malignant glioma	0.000157	0.000853	CcSEcCtD
Bortezomib—Headache—Temozolomide—malignant glioma	0.000156	0.000848	CcSEcCtD
Bortezomib—Nausea—Carmustine—malignant glioma	0.000153	0.000832	CcSEcCtD
Bortezomib—Nausea—Temozolomide—malignant glioma	0.000148	0.000804	CcSEcCtD
Bortezomib—PSMD1—Metabolism—PIK3CA—malignant glioma	6.84e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—malignant glioma	6.81e-06	3.12e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—malignant glioma	6.77e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—malignant glioma	6.77e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—malignant glioma	6.77e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—malignant glioma	6.77e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—malignant glioma	6.77e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—malignant glioma	6.74e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—malignant glioma	6.74e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—malignant glioma	6.74e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—malignant glioma	6.74e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—malignant glioma	6.71e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—malignant glioma	6.7e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—malignant glioma	6.67e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—malignant glioma	6.67e-06	3.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS1—malignant glioma	6.66e-06	3.05e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	6.64e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—malignant glioma	6.64e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—malignant glioma	6.64e-06	3.04e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.63e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—malignant glioma	6.62e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—malignant glioma	6.59e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—malignant glioma	6.57e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—malignant glioma	6.57e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—malignant glioma	6.57e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—malignant glioma	6.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—malignant glioma	6.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—malignant glioma	6.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—malignant glioma	6.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—malignant glioma	6.54e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—IDH2—malignant glioma	6.48e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—malignant glioma	6.48e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.48e-06	2.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—malignant glioma	6.48e-06	2.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—malignant glioma	6.47e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	6.46e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.42e-06	2.94e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAV1—malignant glioma	6.4e-06	2.93e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—malignant glioma	6.25e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—malignant glioma	6.22e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—malignant glioma	6.22e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—malignant glioma	6.22e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—malignant glioma	6.22e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—malignant glioma	6.21e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—malignant glioma	6.21e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—malignant glioma	6.21e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—malignant glioma	6.2e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BCHE—malignant glioma	6.19e-06	2.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—malignant glioma	6.17e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—malignant glioma	6.17e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—malignant glioma	6.17e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—malignant glioma	6.13e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS1—malignant glioma	6.12e-06	2.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—malignant glioma	6.12e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC5A5—malignant glioma	6.11e-06	2.8e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.11e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.11e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2B6—malignant glioma	6.09e-06	2.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—malignant glioma	6.09e-06	2.79e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS1—malignant glioma	6.07e-06	2.78e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.05e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—malignant glioma	6.02e-06	2.76e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	5.88e-06	2.69e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAT—malignant glioma	5.86e-06	2.68e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CG—malignant glioma	5.83e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.78e-06	2.65e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—malignant glioma	5.75e-06	2.63e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.73e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—malignant glioma	5.72e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BCHE—malignant glioma	5.69e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—malignant glioma	5.69e-06	2.61e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	5.68e-06	2.6e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BCHE—malignant glioma	5.64e-06	2.59e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—malignant glioma	5.63e-06	2.58e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC5A5—malignant glioma	5.62e-06	2.58e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—malignant glioma	5.61e-06	2.57e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.6e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—malignant glioma	5.59e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—malignant glioma	5.58e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—malignant glioma	5.58e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—malignant glioma	5.58e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC5A5—malignant glioma	5.58e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—IDH1—malignant glioma	5.57e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—malignant glioma	5.56e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—malignant glioma	5.56e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—malignant glioma	5.54e-06	2.54e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—malignant glioma	5.53e-06	2.54e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NCOR1—malignant glioma	5.53e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—malignant glioma	5.52e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—malignant glioma	5.52e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—malignant glioma	5.52e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—malignant glioma	5.52e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—malignant glioma	5.51e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—malignant glioma	5.5e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—malignant glioma	5.5e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—malignant glioma	5.5e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—malignant glioma	5.5e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—malignant glioma	5.47e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—malignant glioma	5.47e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—malignant glioma	5.47e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—malignant glioma	5.44e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—malignant glioma	5.42e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—malignant glioma	5.39e-06	2.47e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SPHK1—malignant glioma	5.39e-06	2.47e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—malignant glioma	5.37e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2C18—malignant glioma	5.28e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.27e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.22e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—malignant glioma	5.21e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—malignant glioma	5.21e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—malignant glioma	5.21e-06	2.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS1—malignant glioma	5.19e-06	2.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.17e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—malignant glioma	5.13e-06	2.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—malignant glioma	5.13e-06	2.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—malignant glioma	5.13e-06	2.35e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—malignant glioma	5.13e-06	2.35e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—malignant glioma	5.12e-06	2.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—malignant glioma	5.08e-06	2.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—malignant glioma	5.08e-06	2.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—malignant glioma	5.08e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NCOR1—malignant glioma	5.07e-06	2.32e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—malignant glioma	5.06e-06	2.32e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—malignant glioma	5.02e-06	2.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—malignant glioma	5.02e-06	2.3e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—malignant glioma	5.02e-06	2.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—malignant glioma	5.01e-06	2.3e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—malignant glioma	4.95e-06	2.27e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—malignant glioma	4.93e-06	2.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—malignant glioma	4.82e-06	2.21e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—malignant glioma	4.79e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC5A5—malignant glioma	4.76e-06	2.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—malignant glioma	4.74e-06	2.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—malignant glioma	4.74e-06	2.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—malignant glioma	4.74e-06	2.17e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—malignant glioma	4.69e-06	2.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—malignant glioma	4.67e-06	2.14e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—malignant glioma	4.67e-06	2.14e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—malignant glioma	4.65e-06	2.13e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.56e-06	2.09e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—malignant glioma	4.53e-06	2.08e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NCOR1—malignant glioma	4.53e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—malignant glioma	4.51e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.51e-06	2.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—malignant glioma	4.49e-06	2.06e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—malignant glioma	4.47e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.46e-06	2.05e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—malignant glioma	4.43e-06	2.03e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—malignant glioma	4.41e-06	2.02e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—malignant glioma	4.37e-06	2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—malignant glioma	4.35e-06	2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—malignant glioma	4.35e-06	2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—malignant glioma	4.35e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.31e-06	1.97e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—malignant glioma	4.29e-06	1.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—malignant glioma	4.27e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—malignant glioma	4.25e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—malignant glioma	4.25e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—malignant glioma	4.25e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—malignant glioma	4.21e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—malignant glioma	4.21e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—malignant glioma	4.21e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—malignant glioma	4.19e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NCOR1—malignant glioma	4.16e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—malignant glioma	4.15e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—malignant glioma	4.13e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NCOR1—malignant glioma	4.13e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—malignant glioma	4.11e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS1—malignant glioma	4e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—malignant glioma	3.96e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.95e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	3.89e-06	1.78e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—malignant glioma	3.86e-06	1.77e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—malignant glioma	3.84e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—malignant glioma	3.77e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—malignant glioma	3.73e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—malignant glioma	3.72e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—malignant glioma	3.69e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.68e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—malignant glioma	3.63e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—malignant glioma	3.61e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—malignant glioma	3.56e-06	1.63e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—malignant glioma	3.56e-06	1.63e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—malignant glioma	3.56e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NCOR1—malignant glioma	3.53e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.53e-06	1.62e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—malignant glioma	3.51e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—malignant glioma	3.39e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—malignant glioma	3.36e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—malignant glioma	3.36e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—malignant glioma	3.31e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—malignant glioma	3.24e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.21e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—malignant glioma	3.15e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—malignant glioma	3.12e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—malignant glioma	3.09e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—malignant glioma	3.06e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—malignant glioma	2.98e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—malignant glioma	2.96e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—malignant glioma	2.96e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—malignant glioma	2.95e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—malignant glioma	2.89e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—malignant glioma	2.88e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—malignant glioma	2.87e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—malignant glioma	2.86e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.75e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—malignant glioma	2.72e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NCOR1—malignant glioma	2.72e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—malignant glioma	2.72e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.72e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—malignant glioma	2.69e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—malignant glioma	2.62e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—malignant glioma	2.58e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—malignant glioma	2.55e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—malignant glioma	2.53e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—malignant glioma	2.49e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.37e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—malignant glioma	2.35e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—malignant glioma	2.35e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—malignant glioma	2.33e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.3e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—malignant glioma	2.23e-06	1.02e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—malignant glioma	2.22e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—malignant glioma	2.22e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—malignant glioma	2.05e-06	9.38e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—malignant glioma	2.03e-06	9.3e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.02e-06	9.26e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.01e-06	9.19e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—malignant glioma	1.99e-06	9.11e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—malignant glioma	1.95e-06	8.94e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—malignant glioma	1.92e-06	8.79e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.78e-06	8.14e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—malignant glioma	1.76e-06	8.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—malignant glioma	1.73e-06	7.94e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—malignant glioma	1.57e-06	7.19e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—malignant glioma	1.57e-06	7.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.55e-06	7.1e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—malignant glioma	1.53e-06	7.03e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.44e-06	6.62e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—malignant glioma	1.44e-06	6.58e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—malignant glioma	1.43e-06	6.56e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—malignant glioma	1.34e-06	6.13e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—malignant glioma	1.28e-06	5.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.22e-06	5.6e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—malignant glioma	1.18e-06	5.4e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—malignant glioma	1.17e-06	5.36e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—malignant glioma	9.99e-07	4.58e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—malignant glioma	9.44e-07	4.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—malignant glioma	7.71e-07	3.53e-06	CbGpPWpGaD
